India's biotech and biomaterials gain EU plaudits:
This article was originally published in Clinica
Executive Summary
India's biotechnology and biomaterials sectors are among those most suited to co-operation between the EU and India, "given the state-of-the-art of science" in the two regions, suggests a European Commission background paper. Though known as the "third world research superpower", India is still underdeveloped, it says. Despite this, the country's biomaterial sciences are featured for their "high-level of expertise", while the National Institute of Immunology and the International Centre for Genetic Engineering and Biotechnology are described as world class institutions. Biotechnology is not currently a priority of its E2.5 billion ($2.2 billion, 0.72% of GDP) R&D budget, 17% of which is provided by industry.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.